Christopher G. Bunick, MD, PhD

Christopher Bunick, MD, PhD, delves into current data and guidelines to consider when creating custom treatment plans for patients with atopic dermatitis.

Christopher Bunick, MD, PhD, expands on how clinicians can personalize treatment plans for each patient.

Christopher Bunick, MD, PhD, reviews benchmarks for optimal outcomes in patients with atopic dermatitis and compares treatments available.

In our March publication, Winter Editor in Chief Christopher Bunick, MD, PhD, delved into the growing concern of benzene in personal care products. This commentary becomes all the more important in light of the recent findings of high levels of benzene in acne products.

Star Trek may call space “the final frontier,” but it’s really the next exciting frontier for humans. For now, we can learn about the various new innovations and therapies for skin disease at the AAD annual meeting—and continue to strive to improve our patients’ lives here on Earth.

Winter Editor in Chief Christopher Bunick, MD, PhD, looks ahead to a year of dermatology innovations with a reflection on meaningful advances from 2023.

There is a lot of conversation drumming around the boxed warnings for newer JAK inhibitors, and fact versus fiction was discussed at Fall Clinical.

Christopher Bunick, MD, PhD, reviews Cabtreo’s recent FDA approval and what the new triple-combination gel means for acne patients.

Experts conclude their discussion highlighting key takeaways and considerations when using Janus Kinase (JAK) inhibitors as treatment for atopic dermatitis (AD).

Christopher Bunick, MD, PhD, discusses how a patient’s atopic dermatitis (AD) endotype may alter treatment approaches in the future.

Experts offer their clinical advice on when and how to transition patients from a biologic or immunosuppressive agent to a Janus Kinase (JAK) inhibitor.

To further discuss the changing landscape of skin of color representation in dermatology, Christopher Bunick, MD, PhD, and Shawn Kwatra, MD, review how they have seen representation change in their own experiences.

Experts discuss how new data are evolving standards of care for atopic dermatitis (AD) in terms of safety and redefining response to therapy.

Christopher Bunick, MD, PhD, presents the conclusions and major take-aways of the study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Experts discuss the selectivity of Janus Kinase (JAK) inhibitors and considerations when selecting treatment for atopic dermatitis (AD).

Christopher Bunick, MD, PhD, and Ruth Ann Vleugels, MD, MPD, MBA, discuss the nuances of box warnings and how clinicians should assimilate these risk factors in the treatment of atopic dermatitis (AD).

Christopher Bunick, MD, PhD, discusses a novel tool to visualize key safety results of Janus kinase inhibitors in treating patients with atopic dermatitis.

Experts discuss the results of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

In the final part of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.

In part 3 of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.

Christopher Bunick, MD, PhD, introduces the objectives and design of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Ruth Ann Vleugels, MD, MPD, MBA, provides important considerations for clinicians when reflecting upon the safety of oral Janus Kinase (JAK) inhibitors and traditional systemic immunosuppressants.

In part 2 of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.

In part 1 of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the pathogenesis of acne vulgaris, the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.

Christopher Bunick, MD, PhD, discusses the major study conclusions about the safety of upadacitinib as a treatment for atopic dermatitis.

Christopher Bunick, MD, PhD, presents the results of the long-term four-year safety study of upadacitinib as treatment for atopic dermatitis (AD).

Christopher Bunick, MD, PhD, introduces an integrated analysis of phase three studies analyzing the long-term safety of upadacitinib as treatment for atopic dermatitis (AD). He also highlights a burgeoning standard to assess the safety of treatment.

Ruth Ann Vleugels, MD, MPD, MBA, and Christopher Bunick, MD, PhD, provide their clinical experience with Janus Kinase (JAK) inhibitors and the importance of patient compliance with these agents.

Experts discuss a recent network meta-analysis comparing current monotherapies for atopic dermatitis (AD) and how this may change standards of care.

Christopher Bunick, MD, PhD, and Ruth Ann Vleugels, MD, MPD, MBA, discuss the method of action for Janus Kinase (JAK) inhibitors and the pathology of atopic dermatitis (AD).